US20210355229A1 - An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use - Google Patents
An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use Download PDFInfo
- Publication number
- US20210355229A1 US20210355229A1 US17/278,259 US201917278259A US2021355229A1 US 20210355229 A1 US20210355229 A1 US 20210355229A1 US 201917278259 A US201917278259 A US 201917278259A US 2021355229 A1 US2021355229 A1 US 2021355229A1
- Authority
- US
- United States
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 title claims abstract description 119
- 239000000427 antigen Substances 0.000 title claims abstract description 113
- 108091007433 antigens Proteins 0.000 title claims abstract description 113
- 102000036639 antigens Human genes 0.000 title claims abstract description 113
- 239000012634 fragment Substances 0.000 title claims abstract description 104
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 75
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 81
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 49
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 26
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 25
- 241001529936 Murinae Species 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 24
- 102000050320 human TNFRSF4 Human genes 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000010749 gastric carcinoma Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 201000000498 stomach carcinoma Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 101
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 34
- 238000012360 testing method Methods 0.000 description 30
- 235000001014 amino acid Nutrition 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 150000001413 amino acids Chemical class 0.000 description 27
- 239000013604 expression vector Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 102000025171 antigen binding proteins Human genes 0.000 description 18
- 108091000831 antigen binding proteins Proteins 0.000 description 18
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 18
- 230000035772 mutation Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 210000004602 germ cell Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 11
- 102100023410 Phospholipid hydroperoxide glutathione peroxidase Human genes 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 210000003289 regulatory T cell Anatomy 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 210000003162 effector t lymphocyte Anatomy 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 235000020183 skimmed milk Nutrition 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 235000014966 Eragrostis abyssinica Nutrition 0.000 description 6
- 241000206602 Eukaryota Species 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000003915 cell function Effects 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000000032 diagnostic agent Substances 0.000 description 5
- 229940039227 diagnostic agent Drugs 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000012089 stop solution Substances 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 108010042215 OX40 Ligand Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002998 immunogenetic effect Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 2
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000011577 humanized mouse model Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000008073 immune recognition Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 238000012492 Biacore method Methods 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000031852 Gastrointestinal stromal cancer Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- -1 IL-la Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 1
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 238000001265 Jonckheere trend test Methods 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000006395 Meigs Syndrome Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 240000002769 Morchella esculenta Species 0.000 description 1
- 235000002779 Morchella esculenta Nutrition 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010048734 Phakomatosis Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000012338 Therapeutic targeting Methods 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 208000014136 immunodeficiency 16 Diseases 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention belongs to the field of biomedicine and relates to an anti-OX40 antibody, antigen-binding fragment thereof, a chimeric antibody, a humanized antibody comprising the CDR regions of the anti-OX40 antibody, and a pharmaceutical composition comprising the anti-OX40 antibody and antigen-binding fragment thereof, and the use of the same as an anti-cancer agent.
- Cancer is a severe health challenge faced by human society for a long time.
- traditional surgery, chemotherapy, and radiotherapy usually exhibit limited effect.
- Tumor immunotherapy is continuously a hot spot in the field of tumor therapy. Recent studies have proved that enhancing the function of anti-tumor T cells can be used to counteract cancer. There is a lot of evidence showing that tumor cells “escape” from the immune system by inducing active immune tolerance mediated mainly by regulatory T lymphocytes (Treg; Quezda et al. Immunol Rev 2011; 241:104-118). Therefore, the balance between effector T lymphocytes (Teff) and tolerogenic Treg is essential for effective anti-tumor immunotherapy. Therefore, an effective anti-tumor immune response can be obtained by enhancing the effector function of tumor-specific Teff and/or by reducing the inhibitory function of tumor-specific Treg.
- Treg regulatory T lymphocytes
- the CD134 (OX40) receptor has been shown to be a key receptor that mediates these responses (Sugamura, K, Ishii, N, Weinberg, A. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nature Rev Imm 2004; 4:420-431).
- OX40 is a member of the tumor necrosis factor receptor (TNFR) superfamily, and is a glycoprotein with a molecular weight of about 50kDa expressed on the cell surface.
- the extracellular ligand-binding domain of OX40 consists of 4 cysteine-rich domains (CRD).
- the natural ligand of OX40 is OX4OL (CD252), OX40 and OX4OL form an OX40-0X4OL complex.
- OX40 is mainly expressed on activated T cells, and OX40 is a secondary costimulatory molecule that is expressed 24 to 72 hours after activation.
- OX4OL a ligand of OX40, is mainly expressed on activated antigen-presenting cells.
- T lymphocytes expressing OX40 have been confirmed to exist in the draining lymph nodes of patients with various human malignant tumors and cancers.
- SCID severe combined immunodeficiency
- the interaction of OX40 and OX4OL binding domains can enhance anti-tumor immunity, resulting in tumor growth inhibition of various human malignant tumor cell lines, such as lymphoma, prostate cancer, colon cancer and breast cancer.
- OX40 antibodies activate immunity through specific stimulation, improve the patient's own immune system response to tumors, and achieve the purpose of killing tumor cells.
- Related patents are such as W02013038191, WO2015153513, WO2016179517, WO2017096182, CN110078825A, WO2016196228 and so on. So far, the anti-OX40 antibodies developed by companies such as AstraZeneca and BMS have been in phase II clinical trials, and related products from companies such as Genentech and GSK were also in clinical trials.
- the present disclosure provides an anti-OX40 antibody or antigen-binding fragment thereof, which specifically binds to human OX40, and comprises the CDRs shown below:
- heavy chain HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 11, 34 and 13 respectively
- light chain LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 14, 15 and 16 respectively.
- the anti-OX40 antibody or antigen-binding fragment thereof is a murine antibody, chimeric antibody, humanized antibody, human antibody or fragment thereof; in particular, a humanized antibody.
- the CDRs (comprising 3 heavy chain CDRs and 3 light chain CDRs) of the monoclonal antibody or antigen-binding fragment are allowed to comprise 3, 2 or 1 amino acid difference(s) (i.e., CDR variants).
- the CDR variants are obtained by affinity maturation method.
- the affinity (KD) of the monoclonal antibody or antigen-binding fragment to OX40 is less than 10 ⁇ 8 M, less than 10 ⁇ 9 M, or less than 10 1 ° M.
- the murine antibody comprises a heavy chain variable region and a light chain variable region as shown below:
- the humanized antibody comprises FR region(s) derived from human germline or mutant sequence(s) thereof.
- the humanized antibody comprises any one of:
- the anti-OX40 antibody or antigen-binding fragment thereof comprises:
- the anti-OX40 antibody or antigen-binding fragment thereof comprises:
- the anti-OX40 antibody or antigen-binding fragment thereof comprises variable regions as shown below:
- the anti-OX40 antibody or antigen-binding fragment thereof comprises variable regions as shown below:
- the anti-OX40 antibody comprises a constant region; in some particular embodiments, the antibody is a chimeric antibody or a humanized antibody, and the heavy chain constant region of the antibody is derived from human IgG1, IgG2, IgG3, or IgG4 or the mutant sequence(s) thereof, the light chain constant region is derived from human kappa, lambda chain or the mutant sequence(s) thereof; in other particular embodiments, the amino acid sequence of the heavy chain constant region is as shown in SEQ ID NO: 35 or has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 35; the amino acid sequence of the light chain constant region is as shown in SEQ ID NO: 36 or has at least 70%, at least 75%, at least 80%, at least 85%, at
- the heavy chain amino acid sequence of the anti-OX40 antibody is as shown in SEQ ID NO: 39 or 37 or has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 39 or 37, and/or, the light chain amino acid sequence of the anti-OX40 is as shown in SEQ ID NO: 40 or 38 or has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 40 or 38.
- the anti-OX40 antibody comprises:
- the present disclosure also provides an anti-OX40 antibody or antigen-binding fragment thereof, the anti-OX40 antibody or antigen-binding fragment thereof competes with any antibody or antigen-binding fragment thereof described above for the binding to human OX40, or competes with any antibody or antigen-binding fragment thereof described above for binding to the same OX40 epitope.
- composition which comprises:
- the pharmaceutical composition may be prepared in a unit dose form, and the unit dose may comprise 0.01 to 99% by weight of the anti-OX40 antibody or antigen-binding fragment thereof; or the amount of the monoclonal antibody or antigen-binding fragment thereof comprised in the pharmaceutical composition is from 0.1 to 2000 mg/unit dose. In some particular embodiments, the amount of the monoclonal antibody or antigen-binding fragment thereof is from 1 to 1000 mg.
- the monoclonal antibody or antigen-binding fragment thereof may be the one and only active ingredient comprised in the composition; in other particular embodiments, the monoclonal antibody or antigen-binding fragment thereof is used in combination with other active ingredients.
- the present disclosure also provides an isolated nucleic acid molecule, which encodes the anti-OX40 antibody or antigen-binding fragment thereof described above.
- the complementary sequence of the nucleic acid molecule is also included in the scope of this application.
- the present disclosure also provides a vector comprising the nucleic acid molecule described above.
- the vector can be a eukaryotic expression vector, a prokaryotic expression vector or a viral vector.
- the present disclosure also provides a host cell transformed with the vector described above, and the host cell is selected from the group consisting of prokaryotic cells and eukaryotic cells.
- the host cell is a eukaryotic cell.
- the host cell is a mammalian cell, wherein the mammalian cell comprises but not limited to CHO, HEK293, and NSO. It should be understood that the host cell of the present disclosure does not involve any cell capable of developing into humans.
- the present disclosure also provides a method for preparing the anti-OX40 antibody or antigen-binding fragment thereof described above, the method comprises:
- the present disclosure also provides a method for detecting or measuring human OX40, the method comprises:
- the present disclosure also provides a reagent for detecting or measuring human OX40, the reagent comprises any one of the anti-OX40 antibodies or antigen-binding fragment thereof described above.
- the present disclosure also provides a diagnostic agent for diseases related to human OX40, the diagnostic agent comprises the anti-OX40 antibody or antigen-binding fragment thereof described above.
- the present disclosure also provides a method for diagnosing diseases related to human OX40, the method comprises detecting or measuring human OX40 or OX40-positive cells using the anti-OX40 antibody or antigen-binding fragment thereof described above.
- the present disclosure also provides the use of the anti-OX40 antibody or antigen-binding fragment thereof in the preparation of a diagnostic agent for diseases related to human OX40.
- the present disclosure also provides a method for treating disease or disorder, which comprises administering to a subject an effective amount of the anti-OX40 antibody or antigen-binding fragment thereof, or a pharmaceutical composition comprising the OX40 antibody or fragment thereof described above.
- the disease or disorder may be cancer or cell-proliferative disease.
- the cancer is lung cancer, prostate cancer, breast cancer, head and neck cancer, esophageal cancer, gastric carcinoma, colon cancer, colorectal cancer, bladder cancer, cervical cancer, uterine cancer, ovarian cancer, liver cancer, melanoma, kidney cancer, squamous cell carcinoma, hematological cancer or any other disease or disorder characterized by uncontrolled cell growth.
- the hematological cancer comprises but is not limited to acute and chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, bone marrow tissue proliferative disease, multiple myeloma, Hodgkin's disease, non-Hodgkin's lymphoma, B-cell lymphoma, T-cell lymphoma, follicular center cell lymphoma and chronic myeloid leukemia.
- the present disclosure also provides the use of the anti-OX40 antibody or antigen-binding fragment thereof described above, or the pharmaceutical composition comprising the OX40 antibody or fragment thereof described above, in the preparation of a medicine for enhancing the immune response in a human subject.
- the present disclosure also provides the use of the anti-OX40 antibody or antigen-binding fragment thereof described above, or the pharmaceutical composition comprising the OX40 antibody or fragment thereof described above, in the preparation of a medicament for the treatment/prevention of cancer.
- the present disclosure also provides the use of the anti-OX40 antibody or antigen-binding fragment thereof described above, or the pharmaceutical composition comprising the OX40 antibody or fragment thereof described above, in the preparation of a kit.
- the enhanced immune response comprises an increase in the immunostimulatory/effector function of T effector cells, and/or a down-regulation of the immunosuppressive function of T regulatory cells.
- the increase may be the result of cell proliferation
- the down-regulation may be the result of absence of increase in cell number (or decrease in cell number).
- the present disclosure provides the anti-human OX40 antibody or fragment thereof for use in one or more of the following: inhibiting Treg function (for example, inhibiting the suppressive function of Treg), killing OX40-expressing cells (for example, cells expressing high level of OX40), improving effector T cell function and/or improving memory T cell function, reducing tumor immunity, enhancing T cell function and/or reducing OX40-expressing cells.
- Treg function for example, inhibiting the suppressive function of Treg
- OX40-expressing cells for example, cells expressing high level of OX40
- improving effector T cell function and/or improving memory T cell function for example, reducing tumor immunity, enhancing T cell function and/or reducing OX40-expressing cells.
- the present disclosure provides the use of the anti-OX40 antibody or fragment thereof for the following: treating cancer, stimulating immune response in a subject, stimulating antigen-specific T cell response, activating or co-stimulating T cells, increasing cytokines production in T cells (such as IL-2 and/or IFN- ⁇ ), and/or increasing T cell proliferation, reducing or depleting the number of T regulatory cells in tumor, and/or inhibiting the growth of tumor cells.
- the present disclosure also provides the use of the anti-OX40 antibody in the preparation of an agent, the agent is for use in stimulating immune response in a subject, stimulating antigen-specific T cell response, activating or co-stimulating T cells, increasing IL-2 and/or IFN- ⁇ production in T cells and/or T cell proliferation, reducing or depleting the number of T regulatory cells in tumor, and/or inhibiting the growth of tumor cells.
- FIG. 1A to FIG. 1B ELISA test results showing the affinity of murine antibody and chimeric antibody to human OX40.
- FIG. 1A shows the result of the affinity of the murine antibody m2G3 and the chimeric antibody ch2G3, with m2G3-NC and ch2G3-NC as negative controls;
- FIG. 1B shows the result of the affinity of the murine antibody m4B5 and the chimeric antibody ch4B5, with m4B5-NC and ch4B5-NC as negative controls.
- FIG. 2 Test showing the IFN- ⁇ secreted in T cells stimulated by anti-OX40 antibody. The results show that the test OX40 antibody achieves the maximum stimulating effect at a concentration of 10 ng/mL.
- FIG. 3A to FIG. 3B anti-tumor effect of anti-OX40 antibody in mice.
- FIG. 3A shows the changes in tumor volume in different mice after administration;
- FIG. 3B shows the effect of different anti-OX40 antibodies on tumor weight in mice after administration. The results show that on day 20 after dosing treatment, when the dose is at 3 mg/kg, the tumor inhibition rate of 2G3 antibody is up to 97%.
- enhancing T cell function means inducing, causing or stimulating effector or memory T cells, so that they have renewal, sustained or amplified biological functions.
- Examples of enhanced T cell function include: increased secretion of y-interferon from CD8 + effector T cells, increased secretion of y-interferon from CD4 + memory and/or effector T cells, increased proliferation of CD4 + effector and/or the memory T cells, increased proliferation of CD8 + effector T cells, and increased response to antigen (e.g., clearance), when compared with the level before treatment.
- enhancing immune response refers to stimulating, irritating, increasing, improving or enhancing the response of the immune system in mammalian.
- the immune response can be a cellular response (i.e., cell-mediated, such as cytotoxic T lymphocyte-mediated) or a humoral response (i.e., antibody-mediated response), and can be the primary or secondary immune response.
- cellular response i.e., cell-mediated, such as cytotoxic T lymphocyte-mediated
- humoral response i.e., antibody-mediated response
- Examples of enhanced immune response include: increased activity of CD4 + helper T cell and production of cytotoxic T cells.
- the enhanced immune response can be evaluated by some in vitro or in vivo measurements known to those skilled in the art, comprising but not limited to cytotoxic T lymphocyte assay, cytokine release (such as IL-2 production), regression of tumor, and survival of tumor-carrying animals, antibody production, proliferation of immune cells, expression of cell surface marker and cytotoxicity.
- the method enhances cellular immune response, particularly cytotoxic T cell response.
- Tumor immunity refers to the process by which tumors escape from immune recognition and clearance. As a treatment concept, the tumor will be recognized and attacked by the immune system and consequently the patient will be treated, when tumor immunity is weakened in its ability to escape from immune recognition and clearance. Examples of tumor recognition include binding to tumor, shrinkage of tumor, and clearance of tumor.
- Teffs T effector cells
- T cells having cytolytic activity for example, CD4 + and CD8+T cells
- Th cells T helper cells. Teffs secrete cytokines and activate and guide immune cells other than regulatory T cells (Treg cells).
- the anti-OX40 antibodies described in the present disclosure can activate Teff cells, such as CD4 + and CD8 + Teff cells.
- Treg cells mean a specialized type of CD4 + T cells that can suppress the response of other T cells.
- Treg cells are characterized by expressing CD4, a subunit of IL-2 receptor (CD25), and the transcription factor forkhead box P3 (FOXP3) (Sakaguchi, Annu Rev Immunol 22, 531-62 (2004)), and play a vital role in the induction and maintenance of peripheral autologous tolerance. The tolerance targets against antigens expressed by tumors.
- OX40 refers to a receptor that binds to OX40 ligand (OX40-L), and it is a member of the TNF-receptor superfamily. OX40 is also known as tumor necrosis factor receptor superfamily member 4 (TNFRSF4), ACT35, IMD16, TXGP1L and CD134.
- TNFRSF4 tumor necrosis factor receptor superfamily member 4
- ACT35 tumor necrosis factor receptor superfamily member 4
- IMD16 TXGP1L
- CD134 CD134
- the term “OX40” includes any variant or isotype of OX40 that is naturally expressed by a cell. Therefore, the OX40 antibodies or fragment thereof described in the present disclosure can cross-react with OX40 from species other than humans (for example, cynomolgus monkey OX40). Alternatively, the OX40 antibodies or fragment thereof may be specific for human OX40, and does not exhibit cross-reactivity with OX40 of other species.
- OX40 or variant and isoform thereof is isolated from cells or tissues in which it is naturally expressed, or recombinantly produced using techniques well known in the art and/or in the present disclosure.
- OX40 can be natural OX40 derived from any vertebrate source, comprising mammals such as primates (e.g., humans) and rodents (e.g., mice and rats).
- the term covers “full length”, unprocessed OX40 and any forms of OX40 due to processing occurred within a cell.
- the term also covers naturally occurring variants of OX40, such as splicing variants or allelic variants.
- OX40 activation refers to the activation of the OX40 receptor. Generally, OX40 activation leads to signaling.
- an “anti-OX40 antibody” or “an antibody that binds to OX40” refers to an antibody that can bind to OX40 with sufficient affinity so that the antibody can be used as a diagnostic and/or therapeutic agent for targeting OX40.
- reducing OX40-expressing cells means that the anti-OX40 antibody or fragment thereof kills or eliminates OX40-expressing cells. Reducing OX40-expressing cells can be achieved through various mechanisms, such as antibody-dependent cell mediated cytotoxicity (ADCC) and/or phagocytosis.
- ADCC antibody-dependent cell mediated cytotoxicity
- cytokine is a general term for a type of proteins that are released by a population of cells, and the cytokines act as intercellular mediators effecting on another cell.
- cytokines are lymphokines, monocytes; interleukins (ILs), such as IL-1, IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-15; tumor necrosis factors, such as TNF- ⁇ or TNF- ⁇ ; and other polypeptide factors, comprising LIF and kit ligand (KL) and ⁇ -Interferon.
- ILs interleukins
- TNF- ⁇ or TNF- ⁇ tumor necrosis factors
- KL kit ligand
- cytokines involve proteins from natural sources or from recombinant cell culture, and the biologically active equivalents thereof, comprising small molecular entities produced by artificial synthesis, and pharmaceutically acceptable derivatives and salts thereof.
- antibody is not limited by any specific method for producing antibodies. For example, it involves recombinant antibodies, monoclonal antibodies, and polyclonal antibodies.
- the antibodies may be antibodies of different isotypes, for example, IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibodies.
- variable region Near the N-terminus of the antibody heavy chain and light chain, a sequence of about 110 amino acid varies largely, known as variable region (V region); the rest of the amino acid sequence near the C-terminus is relative stable, known as constant region (C region).
- the variable region comprises three hypervariable regions (HVRs) and four framework regions (FRs) having relatively conserved sequence.
- the three hypervariable regions determine the specificity of the antibody, also known as complementarity determining regions (CDRs).
- Each light chain variable region (VL) and each heavy chain variable region (VH) is composed of three CDRs and four FRs, with an order from the amino terminus to the carboxyl terminus being: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
- Three light chain CDRs refer to LCDR1, LCDR2, and LCDR3; three heavy chain CDRs refer to HCDR1, HCDR2 and HCDR3.
- the number and position of the CDR amino acid residues in the LCVR region and HCVR region of the antibody or antigen-binding fragment thereof described in the present disclosure comply with the known Kabat numbering criteria (for LCDR1-3, HCDR1-3).
- recombinant human antibody includes human antibodies prepared, expressed, created or isolated by recombinant method, and the techniques and methods involved are well known in the art, such as:
- Such recombinant human antibodies comprise variable regions and constant regions, which involve specific human germline immunoglobulin sequences encoded by germline genes, but also involve subsequent rearrangements and mutations, such as those occured during the antibody maturation.
- the antibodies of the present disclosure refer to murine antibodies, chimeric antibodies, humanized antibodies, and human antibodies.
- the antibodies are humanized antibodies.
- murine antibody herein refers to monoclonal antibodies against human OX40, which are prepared according to the knowledge and skills in the art. During the preparation, a test object is injected with OX40 antigen, and then splenocytes (B lymphocytes) expressing the antibody which possesses desired sequence or functional characteristics are separated, and then the B lymphocytes are fused with myeloma cells to obtain corresponding hybridoma cells.
- B lymphocytes splenocytes expressing the antibody which possesses desired sequence or functional characteristics
- the murine OX40 antibody or antigen-binding fragment thereof further comprises light chain constant region(s) of murine K, X, chain or variant(s) thereof, or further comprises heavy chain constant region(s) of murine IgG1, IgG2, IgG3 or IgG4, or variant(s) thereof.
- human antibody includes antibodies having variable and constant region(s) from human germline immunoglobulin sequences.
- Human antibodies of the present disclosure may include amino acid residues that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
- human antibody does not refer to such an antibody in which CDR sequences derived from other mammalian species (such as mouse) germline have been grafted onto human framework sequence (i.e., “humanized antibody”).
- humanized antibody refers to antibodies generated by grafting non-human species CDR sequences onto variable region framework of human antibody; that is, antibodies produced from different types of human germline antibody framework sequences. Humanized antibodies overcome the heterogenous response induced by chimeric antibodies which carry a large amount of heterogeneous protein components.
- framework sequences can be obtained from public DNA databases or published references that include germline antibody gene sequences.
- the germline DNA sequences of human heavy chain and light chain variable region genes can be obtained in “VBase” human germline sequence database (www.mrccpe.com.ac.uk/vbase), and also in Kabat, E. A, et al., 1991 Sequences of Proteins of Immunological Interest, 5th edition.
- humanized antibodies of the present disclosure also include humanized antibodies that are obtained after further affinity maturation of CDRs by phage display or yeast display.
- the reduced affinity of the resulting OX40 antibody (or antigen-binding fragment thereof) to the antigen is due to changes occurred in the framework residues which are responsible for the contact with the antigen. Such interaction can be the result of hypermutation in somatic cells. Therefore, there is still a need to graft such donor framework amino acids onto the framework of humanized antibodies.
- the amino acid residues from non-human OX40 antibody or antigen-binding fragment thereof involved in antigen-binding can be identified by detecting the sequence and structure of the variable region of non-human monoclonal antibody. Residues in a CDR donor framework that are different from those in the germline can be considered to be related.
- the sequence can be aligned against the consensus sequence of a subtype or against the consensus sequence of a murine sequence with high percentage of similarity. Rare framework residues are thought to be the result of hypermutation in somatic cells and thus play an important role in binding.
- the antibody light chain of the OX40 humanized antibody further comprises a light chain constant region of a human kappa, lambda chain or the variant thereof.
- the antibody heavy chain of the OX40 humanized antibody further comprises a heavy chain constant region of human IgGl, IgG2, IgG3, IgG4 or the variant thereof; in particular, a human IgG1 heavy chain constant region.
- back mutation refers to reversion of the amino acid mutation(s) in the FR region of a human antibody to the amino acid residue(s) at the corresponding position(s) of the original antibody source.
- the variable region of the humanized antibody can be subjected to minimal back mutation(s) to maintain the activity of the antibody.
- chimeric antibody is an antibody which is formed by fusing the variable region of a non-human antibody with the constant region of a human antibody, the chimeric antibody can alleviate the immune response induced by non-human antibody.
- hybridoma secreting specific murine monoclonal antibody shall be established firstly, a variable region gene is then cloned from mouse hybridomas, then a constant region gene of a human antibody is cloned as desired, the mouse variable region gene is ligated to the human constant region gene to form a chimeric gene which can be inserted into a human vector, and finally the chimeric antibody molecule is expressed in an eukaryotic or prokaryotic industrial system.
- the constant region of a human antibody is selected from heavy chain constant region(s) of human IgG1, IgG2, IgG3 or IgG4 or variant(s) thereof.
- a chimeric antibody comprises human IgG1 heavy chain constant region(s).
- antigen-binding fragment or “functional fragment” of an antibody refers to one or more fragments of the antibody that retain the ability to specifically bind to an antigen (e.g., OX40). It has been shown that fragments of a full-length antibody can be used to achieve function of antigen-binding. Examples of the binding fragments contained in the term “antigen-binding fragment” of an antibody involve:
- Fab fragment a monovalent fragment consisting of VL, VH, CL and CH1 domains
- F(ab′) 2 fragment a bivalent fragment formed by two Fab fragments connected by disulfide bridge(s) in the hinge region;
- CDR complementarity determining region
- VL domain and VH domain of the Fv fragment are encoded by two separate genes, however they can be linked by a synthetic linker by using recombinant methods, to generate a single protein chain in which a monovalent molecular is formed by pairing the VL with VH domain (referred to as single chain Fv (scFv); see, e.g., Bird et al. (1988): Science 242:423-426; and Huston et al (1988) Proc. Natl. Acad. Sci USA 85:5879-5883).
- single chain Fv single chain Fv
- Such single chain antibodies are also intended to be included in the term “antigen binding fragment” of an antibody.
- Antigen binding portions can be produced by recombinant DNA technology or by enzymatic or chemical digestion of an intact immunoglobulin.
- Antibodies can be in the forms of different isotypes, e.g., IgG (e.g., IgG1, IgG2, IgG3 or IgG4 subtype), IgAl, IgA2, IgD, IgE or IgM antibody.
- antigen-binding fragment refers to Fab, Fv, sFv, F(ab′) 2 , linear antibody, single-chain antibody, scFv, sdAb, sdFv, nanobody, peptibody, domain antibody and multispecific antibody (bispecific antibody, diabody, triabody and tetrabody, tandem di-scFv, tandem tri-scFv) having antigen-binding activity.
- Fab is an antibody fragment obtained by treating an IgG antibody molecule with a papain (which cleaves the amino acid residue at position 224 in H chain).
- the obtained fragment has a molecular weight of about 50,000 and antigen-binding activity, in which almost half of H chain to the N-terminus and the entire L chain are bound together through a disulfide bond.
- the Fab in the present disclosure can be produced by treating the monoclonal antibody of the present disclosure (which specifically recognizes human OX40 and binds to the amino acid sequence of extracellular domain or the 3D structure thereof) with papain.
- the Fab can be produced by inserting DNA encoding Fab of the antibody into a prokaryotic expression vector or eukaryotic expression vector and introducing the vector into a prokaryote or eukaryote to express the Fab.
- F(ab)2 refers to an antibody fragment having a molecular weight of about 100,000 and antigen-binding activity, which is obtained by digesting the part downstream of the two disulfide bonds in the hinge region of IgG by pepsin. F(ab′) 2 contains two Fabs connected at the hinge region.
- F(ab′) 2 of the present disclosure can be produced by treating the monoclonal antibody of the present disclosure with pepsin. Also, F(ab′) 2 can be produced by connecting the Fab′ described below via thioether bond or disulfide bond.
- Fab′ is an antibody fragment having a molecular weight of about 50,000 and having antigen-binding activity, which is obtained by cleaving the disulfide bond at the hinge region of the above-mentioned F(ab′) 2 .
- the Fab′ of the present disclosure can be produced by treating F(ab′) 2 of the present disclosure with a reducing agent such as dithiothreitol.
- the Fab′ can be produced by inserting DNA encoding Fab′ of the antibody into a prokaryotic expression vector or eukaryotic expression vector and introducing the vector into a prokaryote or eukaryote to express the Fab′.
- single chain antibody refers to a molecule comprising antibody heavy chain variable domain (or region; VH) connected to antibody light chain variable domain (or region; VL) by a linker.
- Such scFv molecules have general structure of NH 2 -VL-linker-VH—COOH or NH 2 -VH-linker-VL-COOH.
- a suitable linker in the prior art consists of repeated GGGGS amino acid sequence or variant thereof, for example, variant with 1-4 repeats (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448).
- linkers that can be used in the present disclosure are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol.
- the scFv of the present disclosure can be produced by the following steps: obtaining cDNAs encoding the VH and VL of the monoclonal antibody of the present disclosure, constructing a DNA encoding the scFv, inserting the DNA into a prokaryotic or eukaryotic expression vector, and then introducing the expression vector into a prokaryote or eukaryote to express the scFv.
- Diabody is an antibody fragment in which the scFv is dimerized, and it is an antibody fragment having divalent antigen-binding activity. In the divalent antigen-binding activity, the two antigens may be the same or different.
- the diabody of the present disclosure can be produced by the following steps: obtaining cDNAs encoding VH and VL of the monoclonal antibody of the present disclosure, constructing a DNA encoding scFv to make the length of a linker peptide being of 8 or less amino acid residues, inserting the DNA into a prokaryotic or eukaryotic expression vector, and then introducing the expression vector into a prokaryote or eukaryote to express the di ab ody.
- “dsFv” is obtained by replacing one amino acid residue in each of VH and VL with a cysteine residue, and then connecting the substituted polypeptides via a disulfide bond between the two cysteine residues.
- the amino acid residues to be replaced with a cysteine residue can be selected based on three-dimensional structure prediction of the antibody in accordance with known methods (Protein Engineering, 7, 697 (1994)).
- the dsFv of the present disclosure can be produced by the following steps: obtaining cDNAs encoding the VH and VL of the monoclonal antibody of the present disclosure, constructing a DNA encoding the dsFv, inserting the DNA into a prokaryotic or eukaryotic expression vector, and then introducing the expression vector into a prokaryote or eukaryote to express the dsFv.
- CDR-containing peptide is constituted by incorporating one or more regions in the CDRs of VH or VL. Peptides containing multiple CDRs can be linked directly or via a suitable peptide linker.
- the CDR-containing peptide of the present disclosure can be produced by the following steps: constructing DNA encoding the CDRs of VH and VL of the monoclonal antibody in the present disclosure, inserting the DNA into a prokaryotic expression vector or a eukaryotic expression vector, the expression vector is then introduced into prokaryotes or eukaryotes to express the peptide.
- the CDR-containing peptide can also be produced by a chemical synthesis method, such as Fmoc method or tBoc method.
- FR framework
- VL variable domain
- VH variable domain
- CDRs antigen binding loops
- amino acid difference refers to the difference(s) between a polypeptide and the variant(s) thereof at specific amino acid position(s) on the polypeptide fragment, wherein the variant(s) can be obtained by substituting, inserting or deleting amino acid(s) at specific position(s) on the polypeptide.
- epitope refers to the sites on an antigen that specifically bind to an immunoglobulin or antibody.
- the epitope can be formed by adjacent amino acids, or by non-adjacent amino acids which have been brought to be closer due to tertiary folding of a protein.
- the epitope formed by adjacent amino acids is typically retained upon exposure to denaturing solvent, whereas the epitope formed by tertiary folding is typically absent after treatment with denaturing solvent.
- Epitopes typically include at least 3-15 amino acids in a unique spatial conformation.
- Methods for determining epitope are well known in the art, comprising immune-blotting and immune-precipitation assay, and the like. Methods for determining the spatial conformation of an epitope include techniques in the art and techniques described herein, such as X-ray crystallography and two-dimensional nuclear magnetic resonance, and the like.
- the term “specifically binds to” used in present invention refers to the binding of an antibody to an epitope on a predetermined antigen.
- the antibody binds to a predetermined antigen with an equilibrium dissociation constant (KD) of approximately less than 10′ M or even less, and the affinity of the antibody for binding to the predetermined antigen is at least two times higher than that for binding to non-specific antigens (such as BSA) other than the predetermined antigen or closely-related antigens, as measured in an instrument via surface plasmon resonance (SPR) technique, wherein the recombinant human OX40 is used as an analyte while the antibody is used as a ligand.
- SPR surface plasmon resonance
- an antibody recognizing an antigen can be used interchangeably herein with the term “an antibody specifically binding to.”
- KD refers to the dissociation equilibrium constant for particular antibody-antigen interaction.
- the antibody of the present disclosure binds to human OX40 with a dissociation equilibrium constant (K D ) of less than about 10′M, for example, less than about 10 ⁇ 8 M, 10 ⁇ 9 M or 10 ⁇ 10 M or even less; for example, as determined by Surface Plasma Resonance (SPR) technology in Biacore instrument.
- SPR Surface Plasma Resonance
- competition occurs between the antigen-binding proteins, which is determined by an assay in which: an antigen binding protein to be tested (e.g., an antibody or an antigen binding fragment thereof) prevents or inhibits (e.g., reduces) the specific binding of a reference antigen binding protein (e.g., a ligand or reference antibody) to a common antigen (e.g., a OX40 antigen or fragment thereof).
- an antigen binding protein to be tested e.g., an antibody or an antigen binding fragment thereof
- a reference antigen binding protein e.g., a ligand or reference antibody
- a common antigen e.g., a OX40 antigen or fragment thereof.
- assays are, for example, solid phase direct or indirect radioimmunoassay (MA), solid phase direct or indirect enzyme immunoassay (EIA), Sandwich competition assay (see, e.g., Stahli et al, 1983, Methods in Enzymology 9: 242-253); solid phase direct biotin-avidin EIA (see, e.g., Kirkland et al, 1986, J. Immunol.
- MA solid phase direct or indirect radioimmunoassay
- EIA enzyme immunoassay
- Sandwich competition assay see, e.g., Stahli et al, 1983, Methods in Enzymology 9: 242-253
- solid phase direct biotin-avidin EIA see, e.g., Kirkland et al, 1986, J. Immunol.
- solid phase direct labeling assay solid phase direct labeling sandwich assay (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press); solid phase direct labeling RIA with I-125 label (see, e.g., Morel et al, 1988, Molec. Immunol. 25: 7-15); and direct labeling RIA (Moldenhauer et al, 1990, Scand. J. Immunol. 32: 77-82).
- the assay involves the use of a purified antigen capable of binding to both an unlabeled test antigen binding protein and a labeled reference antigen binding protein (the antigen is loaded on a solid surface or cell surface).
- Antigen-binding proteins identified by competitive assay includes: antigen-binding proteins that bind to the same epitope as the reference antigen-binding protein; and antigen-binding proteins that bind to an epitope that is sufficiently close to the epitope to which the reference antigen-binding protein binds, where the two epitopes spatially interfere with each other to hinder the binding. Additional details regarding methods for determining competitive binding are provided in the examples herein.
- a competitive antigen-binding protein when present in excess, it will inhibit (e.g., reduce) at least 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75% or even more of the specific binding of the reference antigen-binding protein to the common antigen. In certain cases, the binding is inhibited by at least 80-85%, 85-90%, 90-95%, 95-97% or even more.
- cross-reaction refers to the ability of the antibody of the present invention to bind to OX40 from different species.
- an antibody of the present invention that binds to human OX40 can also bind to OX40 from another species.
- Cross-reactivity is measured by detecting the specific reactivity with purified antigen in binding assays (e.g., SPR and ELISA), or by detecting the binding or functional interaction with cells physiologically expressing OX40.
- binding assays e.g., SPR and ELISA
- Methods for determining cross-reactivity include standard binding assays as described herein, such as surface plasmon resonance analysis (SPR), or flow cytometry.
- inhibitortion or “blocking” are used interchangeably, and covers both partial and complete inhibition/blocking.
- inhibition of growth e.g., when applied to cells
- inhibition of growth is intended to refer to any measurable decrease in cell growth.
- inducing an immune response and “enhancing an immune response” are used interchangeably, and refer to an immune response against the stimulation of a specific antigen (i.e, passive or adaptive).
- induction in the context of inducing CDC or ADCC refers to the stimulation of a specific direct cell killing mechanism.
- ADCC antibody-dependent cell-mediated cytotoxicity
- FcR Fc receptors
- cytotoxic cells such as NK cells, neutrophils, and macrophages
- NK cells The main cells that mediate ADCC express FcyRIII alone, while monocytes express FcyRI, FcyRII, and FcyRIII.
- FcR expression on hematopoietic cells is summarized in Table 3 on page 464 in Ravetch and Kinet, Annu. Rev. Immunol.
- an in vitro ADCC assay can be performed, such as that described in U.S. Pat. No. 5,500,362 or U.S. Pat. No. 5,821,337 or U.S. Pat. No. 6,737,056 (Presta).
- the effector cells useful for such assays include PBMC and NK cells.
- the ADCC activity of the molecule of interest can be assessed in vivo, for example in an animal model such as that disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998).
- the Fc segment of IgG can be modified to reduce or eliminate the ADCC effect of antibodies.
- the modification refers to mutations in the heavy chain constant region of the antibody, such as mutations selected from the group consisting of N297A, L234A, L235A of IgG1; IgG2/4 chimera, F235E of IgG4, and L234A/E235A mutation.
- complement dependent cytotoxicity refers to the lysis of target cells in the presence of complement.
- the classical pathway of complement activation is initiated by the binding of the first component of the complement system (C1q) to an antibody (of the appropriate subclass), which has bound to its cognate antigen.
- C1q first component of the complement system
- an antibody of the appropriate subclass
- a CDC assay can be performed, for example as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996).
- Polypeptide variants having modified Fc region amino acid sequence(s) (polypeptides with variant Fc region(s)) as well as having increased or decreased C1q-binding ability are described in, for example, U.S. Pat. No. 6,194,551B1 and WO 1999/51642. See also, for example, Idusogie et al., J. Immunol. 164: 4178-4184 (2000).
- nucleic acid molecule refers to DNA molecule and RNA molecule.
- a nucleic acid molecule may be a single-stranded or double-stranded, but in particular double-stranded DNA.
- a nucleic acid is considered to be “operably linked”, when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to an encoding sequence, when it has effect on the transcription of the sequence.
- vector refers to a nucleic acid molecule capable of delivering another nucleic acid to which it has been linked.
- the vector is a “plasmid,” which refers to a cyclic double-stranded DNA loop into which additional DNA segment(s) may be ligated.
- the vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome.
- the vectors disclosed herein are capable of self-replicating in the host cell into which they are introduced (e.g., bacterial vectors having a bacterial replication origin and episomal mammalian vectors), or may be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the genome of the host (e.g., non-episomal mammalian vectors).
- mice can be immunized with human OX40 or fragments thereof, and the resulting antibodies can then be renatured, purified, and sequenced for amino acid sequences by using conventional methods well known in the art.
- Antigen-binding fragments can also be prepared by conventional methods.
- the antibodies or antigen binding fragments thereof of the present disclosure are engineered to insert one or more human FR regions onto non-human CDR regions.
- Human FR germline sequences can be obtained from ImMunoGeneTics (IMGT) website http://imgt.cines.fr, or from The Immunoglobulin Facts Book, 2001 ISBN012441351, by aligning against the IMGT human antibody variable germline gene database using MOE software.
- IMGT ImMunoGeneTics
- the antibodies or the antigen-binding fragments in the present disclosure may be prepared and purified using conventional methods.
- cDNA sequences encoding a heavy chain and a light chain may be cloned and recombined into GS expression vector.
- the recombinant immunoglobulin expression vector then may be stably transfected into CHO cells.
- mammalian expression system may result in glycosylation of antibodies, typically at the highly conserved N-terminus in the Fc region.
- Stable clones may be obtained through expression of an antibody specifically binding to human antigen. Positive clones may be expanded in a serum-free culture medium for antibody production in bioreactors.
- Culture medium into which an antibody has been secreted, may be purified and collected by conventional techniques.
- the antibody may be subjected to filtration and concentration using common techniques. Soluble mixtures and multimers may be effectively removed by common techniques, such as molecular sieve or ion exchange.
- the obtained product shall be immediately frozen, for example at ⁇ 70° C., or may be lyophilized.
- the monoclonal antibody refers to an antibody obtained from a single clone of cell strain which is but not limited to eukaryotic, prokaryotic, or phage clone of cell strain.
- Monoclonal antibodies and antigen-binding fragment thereof can be obtained, for example, by hybridoma technologies, recombinant technologies, phage display technologies, synthetic technologies (e.g., CDR-grafting), or other technologies known in the art.
- host cell refers to a cell into which an expression vector has been introduced.
- Host cells may include microorganisms (such as bacteria), plants or animal cells.
- Bacteria susceptible to be transformed include members of the Enterobacteriaceae, such as Escherichia coli or Salmonella; Bacillaceae, such as Bacillus subtilis; Pneumococcus; Streptococcus and Haemophilus influenzae.
- Suitable microorganisms include Saccharomyces cerevisiae and Pichia pastoris.
- Suitable animal host cell lines include CHO (Chinese Hamster Ovary Cell Line), NSO and 293 cells.
- Constant modification or “conservative replacement or substitution” means the substitution of other amino acids showing similar characteristics (such as charge, side chain size, hydrophobicity/hydrophilicity, main chain conformation and rigidity, etc) for the amino acids in a protein, such that the modification can be frequently performed without changing the biological activity of the protein.
- Those skilled in the art know that, generally, single amino acid substitution in a non-essential region of a polypeptide does not substantially change the biological activity (see for example, Watson et al. (1987) Molecular Biology of the Gene, The Benjamin/Cummings Pub. Co., Page 224 (4th edition)).
- the substitution of amino acids with similar structure or function is unlikely to result in the loss of biological activity.
- Effective amount involves an amount sufficiently to ameliorate or prevent a symptom or sign of a medical symptom or condition. Effective amount also means an amount sufficiently to allow or facilitate diagnosis. An effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition being treated, the general health of the patient, the route and dosage of administration and the severity of side effects. An effective amount can be the maximal dosage or dosing protocol that avoids significant side effects or toxic effects.
- Exogenous refers to substances that are produced outside an organism, cell, or human body, depending on the context.
- Endogenous refers to substances that are produced within an organism, cell, or human body, depending on the context.
- the “mutated sequence” mentioned in the present disclosure refers to a nucleotide sequence and amino acid sequence having various percentage sequence identity to those of the present disclosure, after modifying the nucleotide sequence and amino acid sequence of the present disclosure by appropriate substitution, insertion or deletion.
- the sequence identity may be at least 85%, 90% or 95%, non-limiting examples include 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and 100%. Sequence comparison between two sequences and determination of identity percent can be performed using the BLASTN/BLASTP algorithm available on the National Center For Biotechnology Institute website, with default settings.
- homology refers to a sequence similarity between two polynucleotide sequences or between two polypeptide sequences.
- a position in both of the two sequences to be compared is occupied by the same base or amino acid monomer subunit, e.g., when a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous at that position.
- the percent of homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of all positions to be compared and then multiplied by 100.
- the expressions “cell,” “cell line,” and “cell culture” are used interchangeably and all such designations involve progeny thereof.
- “transformant” and “transformed cell” include the primary subject cells and culture derived therefrom, regardless of the number of passages. It should be also understood that all progeny may not be precisely identical in the aspect of DNA content, due to intended or unintended mutations. Mutant progeny exhibiting the same function or biological activity as screened for the originally transformed cells are included. Where distinct designations are mentioned, it will be clearly understood according to the context.
- PCR polymerase chain reaction
- sequence information at the terminus of or beyond the region of interest needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to the complementary strand of the template to be amplified.
- the 5′ terminus nucleotides of the two primers can be identical to the ends of the material to be amplified.
- PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genome and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis et al. (1987) Cold Spring Harbor Symp. Ouant. Biol. 51:263; Erlich editor, (1989) PCR TECHNOLOGY (Stockton Press, NY).
- the PCR used in the present disclosure is considered to be one example (but not the only one) of polymerase reaction methods for amplifying a nucleic acid sample to be testes.
- the method comprises the use of nucleic acid sequences known as primers in combination with nucleic acid polymerase to amplify or generate a specific portion of nucleic acid.
- “Optional” or “optionally” means that the event or circumstance that follows may (but does not necessarily) occur, and the description includes the instances where the event or circumstance does or does not occur.
- “optionally contains 1-3 antibody heavy chain variable region(s)” means the antibody heavy chain variable region(s) with specific sequence can be, but need not be, present.
- “Pharmaceutical composition” refers to a mixture containing one or more antibodies or the antigen binding fragments thereof according to the present disclosure, and other chemical components, such as physiologically/pharmaceutically acceptable carriers or excipients.
- the pharmaceutical composition aims at promoting the administration to an organism, facilitating the absorption of the active component and thereby exhibiting a biological effect.
- cancer refers to or describes a physiological condition in mammals, characterized by unregulated cell growth.
- examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies.
- cancers include, but are not limited to, squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer (including small cell lung cancer, non-small cell lung cancer, adenocarcinoma, and squamous cell carcinoma of the lung), peritoneal cancer, hepatocellular carcinoma, gastric carcinoma (including gastrointestinal cancer and gastrointestinal stromal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, urethral cancer, liver tumor, breast cancer, colon cancer, rectum cancer, colorectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, anal cancer, penile cancer, melanoma, superficial spreading melanoma, malignant freckle mole melanoma, acral melanoma, nodular melanoma, multiple myeloma and B-cell lympho
- cancers suitable to be treated by the OX40 antibody or the fragment thereof in the present disclosure include breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, glioblastoma, non-Hodgkin's lymph Tumor (NHL), renal cell carcinoma, prostate cancer, liver cancer, pancreatic cancer, soft tissue sarcoma, Kaposi's sarcoma, carcinoid carcinoma, head and neck cancer, ovarian cancer, mesothelioma, and multiple Myeloma.
- the cancer is selected from the group consisting of: non-small cell lung cancer, glioblastoma, neuroblastoma, melanoma, breast cancer (e.g.
- cancer is selected from the group consisting of: non-small cell lung cancer, colorectal cancer, glioblastoma, and breast cancer (e.g. triple negative breast cancer), including metastases of those cancers.
- cell proliferative disorder and “proliferative disorder” refer to disorders associated with a certain degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder refers to cancer.
- tumor refers to all neoplastic cell growth and proliferation, regardless of malignant or benign, and all pre-cancerous and cancerous cells and tissues.
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- cancer cancer
- administering when applied to an animal, human, subject, cell, tissue, organ or biological fluid, refers to contacting an exogenous pharmaceutical, therapeutic, diagnostic agent, or composition with the animal, human, subject, cell, tissue, organ or biological fluid.
- administering can refer to such as therapeutic, pharmacokinetic, diagnostic, research and experimental methods. Treatment of a cell involves contacting a reagent with a cell, as well as contacting a reagent with a fluid wherein said fluid is in contact with the cell.
- administering also mean in vitro and ex vivo treatment of e.g. a cell, by using a reagent, diagnostic, binding composition, or by using another cell.
- Treatment when applied to a human, veterinary or a research subject, refers to therapeutic treatment, prophylactic or preventative measures, research as well as diagnostic applications.
- “To treat” means internal or external administration of a therapeutic agent (such as a composition comprising any of the antibodies or antigen-binding fragment thereof of the present disclosure; or a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof) to a patient having one or more disease or symptom for which the therapeutic agent was known to show therapeutic activity.
- a therapeutic agent such as a composition comprising any of the antibodies or antigen-binding fragment thereof of the present disclosure; or a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof
- the therapeutic agent is administered in an amount effective to alleviate one or more disease or symptom in the treated patient or population, either by inducing the regression of such symptom(s), or by inhibiting the progression of such symptom(s) to any clinically measurable degree.
- the amount of a therapeutic agent that is effective to alleviate any particular disease or symptom may vary according to factors such as the disease state, age and weight of the patient, and the ability of the medicament to elicit a desired effect in the patient. Whether a disease symptom has been alleviated can be assessed by any clinical measurement typically used by physicians or other skilled healthcare providers to assess the severity or progression status of that symptom.
- the embodiment of the present disclosure may not be effective in alleviating each disease symptom of interest, it should alleviate the target disease symptom(s) of interest in a statistically significant number of subjects as determined by any statistical test known in the art such as Student's t-test, chi-square test, U-test according to Mann and Whitney, Kruskal-Wallis test (H-test), Jonckheere-Terpstra-test and Wilcoxon-test.
- any statistical test known in the art such as Student's t-test, chi-square test, U-test according to Mann and Whitney, Kruskal-Wallis test (H-test), Jonckheere-Terpstra-test and Wilcoxon-test.
- prevention of cancer refers to delaying, inhibiting or preventing the onset of cancer in mammals; the initiation of the development of cancer or tumor has not been confirmed in the mammals, but the mammals have been identified to be susceptible to the cancer by for example genetic screening or other methods.
- the term also includes the treatment of a mammal suffering from precancerous condition in order to prevent the precancerous condition from progressing towards malignant tumor or even to achieve regression.
- the library of anti-human OX40 monoclonal antibodies was generated by immunizing mice.
- Experimental mice of the BalB/C and A1J strains Center for Comparative Medicine, Yangzhou University, Animal Production License Number; SOCK(Jiangsu)2017-007), female, 10-week old.
- Immune antigen was human OX40 recombinant protein with Fc tag (OX40-Fc: OX40 Leu29-Ala216 (Accession# NP 003318), fused with Fc), and was purchased from Acro Biosystems under catalog number # OX40-H5255, expressed in HEK293, and then purified according to conventional method.
- OX40-Fc was emulsified with Freund's adjuvant: Freund's complete adjuvant (sigma-aldrich, F5881-10ML) was used for the first immunization, and Freund's incomplete adjuvant (sigma-aldrich, F5506-10ML) was used for the reset of booster immunizations.
- the ratio of antigen to adjuvant was 1:1, and 25 ⁇ g protein/200 ⁇ l/mouse was injected for each immunization.
- the antibody titer in mouse serum and the neutralizing activity of blocking the binding of OX40/0X4OL were determined with mouse serum by ELISA method as described in Example 2.
- the mice with strong serum titer, affinity and ability for blocking ligand binding were selected for a final immunization and then were sacrificed.
- the spleen cells were fused with SP2/0 myeloma cells (ATCC® CRL-1581TM) and innoculated onto a plate to obtain hybridomas.
- Target hybridomas were selected by indirect ELISA, capture ELISA and cell-based functional screening as shown in Example 2, and monoclonal antibody strains were established by limited dilution method.
- the established 19 strains of OX40 mouse monoclonal antibodies were produced by serum-free expression, and purified mouse monoclonal antibodies were obtained by protein A affinity chromatography.
- Hybridoma cells secreting activated anti-OX40 antibody were selected by indirect ELISA, capture ELISA and cell functional activity screening.
- the brief procedure of functional screening was as follows: GS-H2/OX40 stable cell line was cultivated (purchased from Genscript, cat# M00608). Diluted antibody to be tested and OX4OL (Sino Biological, 13127-H04H) solution were prepared, and added into GS-H2/OX40 cells at logarithmic growth phase.
- RNAs were extracted from cells by conventional RNA extraction technology, and then the PCR products of the variable regions of the monoclonal antibodies were obtained by reverse transcription polymerase chain reaction (RT-PCR). The PCR products were resolved and recovered by agarose gel, then cloned into a gene vector which was then transformed into E.coli. Several transformed colonies were randomly selected, and the variable regions of monoclonal antibodies were amplified by PCR for gene sequencing. The corresponding sequences of the obtained exemplary murine monoclonal antibodies are shown below.
- the heavy and light variable region sequences of the murine monoclonal antibody m4B5 are as follows:
- m4B5 heavy chain variable region SEQ ID NO: 1 QVQLKQSGPGLVQPSQSLSITCTVSGFSLTSYGLHWFRQSPGKGLEWLGV IWSGGSTDYNAAFISRLSISKDDSKSQVFFKMNSLQADDTAIYYCAREEY DVWGTGTTVTVSS; m4B5 light chain variable region: SEQ ID NO: 2 DIQMTQTASSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYY TSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDVATYFCQQGNTLPWTFGG GTKLEIK.
- the heavy and light chain variable region sequences of the murine monoclonal antibody m2G3 are as follows:
- m2G3 heavy chain variable region SEQ ID NO: 9 QVQLKESGPGLVASSQSLSITCTVSGFSLSRYSVHWVRQPPGKGLEWLGM IWDGGNTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCARNPL YFSYAMDYWGQGTSVTVSS; m2G3 light chain variable region: SEQ ID NO: 10 DIQMTQSTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIIY TSRLQSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQVNTFPFTFGS GTKLEIK.
- 20xcoating buffer was diluted to lx by using deionized water.
- 100 ⁇ L of human OX40-His antigen (Acro biosytems, OXL-H52Q8) prepared by using 1 xcoating buffer (carbonate buffer) to a final concentration of 2 ⁇ g/mL was added to each well, and incubated at 4° C. overnight or 37° C. for 2 h.
- the plate was washed once with PBST, 200 ⁇ L of blocking solution (PBST containing 5% skimmed milk) was added to each well, incubated at 37° C. for 2 h, and the plate was washed for 4 times with PB ST.
- PBST blocking solution
- the antibody to be tested was 5-fold diluted from the concentration of 10000 ng/ml, resulting in seven gradients, namely 10000 ng/ml, 2000 ng/ml, 400 ng/ml, 80 ng/ml, 16 ng/ml, 3.2 ng/ml, and 0.64 ng/ml, blank wells merely contained dilution solution, i.e., 2.5% skimmed milk in PBST), and incubated at 37° C. for 40 minutes.
- dilution solution i.e., 2.5% skimmed milk in PBST
- the plate was washed for 4 times with PBST, and the enzyme-labeled secondary antibody (HRP-labeled goat anti-mouse IgG, purchased from Jackson Immunoresearch, Cat# 115036071 or HRP-labeled goat anti-human IgG, purchased from Jackson Immunoresearch, Cat# 109036098) was diluted with PBST buffer; 100 ⁇ L was added to each well and incubated at 37° C. for 40min. The plate was washed for 4 times with PBST, and 100 ⁇ L TMB developing solution was added to each well, incubated for 3-15 minutes in dark at room temperature, and 50p1 stop solution (1M sulfuric acid) was added to each well. The parameters were set for the microplate reader, the OD value was read at 450-630nm, and the test data were saved.
- HRP-labeled goat anti-mouse IgG purchased from Jackson Immunoresearch, Cat# 115036071 or HRP-labeled goat anti-human IgG, purchased from
- 20xPBS buffer was diluted to 1 xwith deionized water.
- 100 ⁇ L of GAM secondary antibody (Jackson Immunoresearch, 115-006-071) prepared with 1 xPBS to a final concentration of 2 ⁇ g/mL was added to each well, and incubated at 4° C. overnight or 37° C. for 2 h; the plate was washed once with PBST, 200 ⁇ L blocking solution (PBST containing 5% skimmed milk) was added to each well, incubated at 37° C. for 2 h, and the plate was washed with PBST for 4 times.
- GAM secondary antibody Jackson Immunoresearch, 115-006-071
- the antibody to be tested was 5-fold diluted from the concentration of 10000 ng/ml, resulting in seven gradients, namely 10000 ng/ml, 2000 ng/ml, 400 ng/ml, 80 ng/ml, 16 ng/ml, 3.2 ng/ml, and 0.64 ng/ml, blank wells merely contained dilution solution, i.e., 2.5% skimmed milk in PBST), and incubated at 37° C. for 40 minutes.
- dilution solution i.e., 2.5% skimmed milk in PBST
- the plate was washed for 4 times with PBST, human OX40-FC-biotin (Acro biosystem, OXO-H5255, labeled biotin) was diluted with 2.5% skimmed milk in PBST, 100 ⁇ l was added to each well, incubated at 37° C. for 40 min, and the plate was washed for 4 times with PB ST. 100 ⁇ L TMB developing solution was added to each well, incubated for 3-15 minutes in dark at room temperature, 50 ⁇ l stop solution (1M sulfuric acid) was added to each well. The parameters were set for the microplate reader, the OD value was read at 450-630nm, and the test data were saved.
- human OX40-FC-biotin Acro biosystem, OXO-H5255, labeled biotin
- Blocking ELISA of ligand binding 20 ⁇ coating buffer was diluted to lx by using deionized water, 100 ⁇ L of OX40L-His antigen (Acro biosytems, OXL-H52Q8) prepared by using 1 ⁇ coating buffer (carbonate buffer) to a final concentration of 2 ⁇ g/mL was added to each well, and incubated at 4° C. overnight or 37° C. for 2 h. The plate was washed once with PBST, 200 ⁇ L of blocking solution (PBST containing 5% skimmed milk) was added to each well, incubated at 37° C.
- OX40L-His antigen Acro biosytems, OXL-H52Q8
- mice serum/antibody was gradient-diluted with pre-prepared 200 ng/ml human OX40-Fc solution (prepared in 2.5% skimmed milk), and then pre-incubated at room temperature for 40 minutes, then added to the blocked OX4OL plate at 100 ⁇ L/well, and incubated for 40min; the plate was washed for 4 times with PBST; HRP-labeled goat anti-human secondary antibody (GAH-HRP, Jackson Immunoresearch, 109-035-006) was diluted with PBST buffer; 100 ⁇ L was added to each well and incubated at 37° C. for 40min.
- GSH-HRP Jackson Immunoresearch, 109-035-006
- the plate was washed for 4 times with PBST, and 100 ⁇ L TMB developing solution was added to each well, incubated for 3-15 minutes in dark at room temperature, and 50 ⁇ l stop solution (1M sulfuric acid) was added to each well.
- the parameters were set for the microplate reader, the OD value was read at 450-630nm, and the test data were saved.
- the murine antibody m2G3 and m4B5 heavy chain variable region (VH) in combination with human immunoglobulin heavy chain constant region, and light chain variable region (VL) in combination with human immunoglobulin Kappa light chain constant region were separately cloned into eukaryotic expression vector, which was then transfected into cells to produce mouse-human chimeric antibodies.
- the heavy chain vector was designed as follows: signal peptide+heavy chain variable region sequence+human IgG1 constant region sequence.
- the light chain vector was designed as follows: signal peptide +light chain variable region sequence +human Kappa constant region sequence.
- the above sequences were inserted into pCEP4 vector (Thermofisher, V04450). After obtaining the vector plasmid, the plasmid was extracted and was delivered to sequencing for verification. The qualified plasmid was transfected into human 293F cells with PEI and cultured continuously, and the 293F cells were cultivated in serum-free medium (Shanghai OPM biosciences, OPM-293 CD03) to reach logarithmic growth phase for cell transfection.
- chimeric antibody light chain plasmid and 23.6 ⁇ g of chimeric antibody heavy chain plasmid were dissolved in 10 ml Opti-MEM(IDI Reduced Serum Medium (GIBCO, 31985-070) and mixed well, then 200m PEI was added, mixed well, and incubated at room temperature for 15min, and added into 50mL cells.
- Cell culture conditions 5% CO2, 37° C., 125 rpm/min. During the culture period, medium supplementary was added on day 1 and day 3 until the cell viability was less than 70%, and the cell supernatant was collected and centrifuged.
- the cell culture solution was loaded onto affinity column for antibody purification, the column was washed with phosphate buffer, eluted with glycine-hydrochloric acid buffer (pH 2.7, 0.1M Gly-HCl), neutralized with 1M Tris hydrochloric acid pH 9.0, and dialyzed against phosphate buffer, and purified chimeric antibodies Ch2G3 and Ch4B5 were finally obtained.
- m2G3-NC (-NC represents negative control), Ch2G3-NC, m4B5-NC and Ch4B5-NC were negative controls, which share the same constant regions as that used in m2G3, Ch2G3, m4B5, and Ch4B5, respectively, however, the variable regions thereof do not recognize OX40.
- the well-plate was coated with anti-CD3 antibody (Chempartner, A05-001), placed at 4° C. overnight and washed for 3 times with PBS; Jurkat-NF-Kb luc-hOX40 cells (ATCC, TIB-152 stable cell line constructed by Shanghai ChemPartner) and Raji cells (ATCC, CCL-86) were harvested, resuspended and mixed. 50 ⁇ l/well of the diluted antibody to be tested and 50 ⁇ l/well of the mixed two types of cells were added into the plate, and the plate was incubated at 37° C. in 5% CO 2 incubator for 5 hours.
- VH heavy chain variable region
- VL light chain variable region
- the heavy chain vector was designed as follows: signal peptide+mutated heavy chain variable region sequence+human IgG1 constant region sequence.
- the light chain vector was designed as follows: signal peptide +mutated light chain variable region sequence +human Kappa constant region sequence.
- the above sequences were separately inserted into pCEP4 vector (Thermofisher, V04450).
- the expression vectors were synthesized by a third-party gene synthesis company according to the above design. After obtaining the vector plasmid, the plasmid was extracted and sent to sequencing for verification. The qualified plasmid was transfected into human 293F cells with PEI and cultured continuously, and the 293F cells were cultivated in serum-free medium (Shanghai OPM biosciences, OPM-293 CD03) to reach logarithmic growth phase for cell transfection.
- Cell culture conditions 5% CO 2 , 37° C., 125 rpm/min. During the culture period, medium supplementary was added on day 1 and day 3 until the cell viability was less than 70%, and the cell supernatant was collected and centrifuged. After centrifugation and filtration, the cell culture solution was loaded onto affinity column for antibody purification, the column was washed with phosphate buffer, eluted with glycine-hydrochloric acid buffer (pH 2.7, 0.1M Gly-HCl), neutralized with 1M Tris hydrochloric acid pH 9.0, and dialyzed against phosphate buffer, and purified humanized antibodies were finally obtained.
- sequences of the humanized variable regions are as follows:
- sequences of the humanized variable regions of m4B5 are as follows:
- hu4B5 VL0 SEQ ID NO: 21 DIQMTQSPSSLSASVGDRVTITC RASQDISNYLN WYQQKPGKVPKLLIY Y TSRLHS GVPSRFSGSGSGTDFTLTISSLQPEDVATYYC QQGNTLPWT FGG GTKVEIK ;
- hu4B5 VL1 SEQ ID NO: 22 DIQMTQSPSSLSASVGDRVTITC RASQDISNYLN WYQQKPGKVPKLLIY Y TSRLHS GVPSRFSGSGSGTDYTLTISSLQPEDVATYYC QQGNTLPWT FGG GTKVEIK ;
- hu4B5 VL2 SEQ ID NO: 23 DIQMTQSPSSLSASVGDRVTITC RASQDISNYLN WYQQKPGGVPKLLIY Y TSRLHS GVPSRFSGSGSGTDYTLTISSLQPEDVATYYC QQG
- hu2G3 VH1.1 SEQ ID NO: 31 QVQLQESGPGLVKPSETLSLTCTVSGYSIS RYSVH WVRQPPGKGLEWIG M IWDGGNTDYNAALKS RFTISRDNAKNTLYLQMNSLRAEDTAVYYCAR NPL YFSYAMDY WGQGTLVTVSS; >hu2G3 VH1.2 SEQ ID NO: 32 QVQLQESGPGLVKPSQTLSLTCTVSGFSLS RYSVH WVRQPPGKGLEWIG M IWDGGNTDYAAPVKG RFTISRDDSKNTLYLQMNSLKTEDTAVYYCAR NPL YFSYAMDY WGQGTLVTVSS .
- the HCDR2 sequence obtained after mutation is as follows:
- the heavy chain variable regions hu2G3 VH1.1 and hu2G3 VH1.2 were combined with the light chain variable region hu2G3 VL to form new optimized humanized antibodies, see Table 7.
- the humanized antibodies described above were tested for affinity (refer to the capture ELISA in Example 2), and the test results showed that the humanized molecules can bind to OX4O.
- the light chain variable region sequence as described above was combined with the light chain constant region sequence to form the final light chain sequences, and the heavy chain variable region sequence as described above was combined with the heavy chain constant region to form the final heavy chain sequences.
- the specific light and heavy chain constant regions are not limited to the antibody constant regions disclosed in the present disclosure. Other light and heavy chain constant regions and the mutants thereof known in the art can also be used to increase the performance of the antibody.
- the exemplary constant regions are as follows:
- IgG1 heavy chain constant region SEQ ID NO: 35 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSPGK; kappa light chain constant region: SEQ ID NO: 36 RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWK
- amino acid sequences of exemplary full-length 2G3 and hu4B5-V7 (also known as 4B5) antibody are as follows:
- 2G3 heavy chain SEQ ID NO: 37 QVQLQESGPGLVKPSETLSLTCTVSGYSISRYSVHWVRQPPGKGLEWIGM IWDGGNTDYNAALKSRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARNPL YFSYAMDYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTY ICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGS
- the positive control GPX4 was prepared with reference to 1A7. gr.1 taught in the patent WO2015153513, and the heavy and light chain amino acid sequences thereof are as follows:
- GPX4 heavy chain SEQ ID NO: 41 EVQLVQSGAEVKKPGASVKVSCKASGYTFTDSYMSWVRQAPGQGLEWIGD MYPDNGDSSYNQKFRERVTITRDTSTSTAYLELSSLRSEDTAVYYCVLAP RWYFSVWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGS
- the Biacore method is a well-recognized method for objectively detecting the affinity and kinetics between proteins.
- the recombinant anti-OX40 antibody to be tested of the present invention was covalently connected to the CM5 (GE) chip by NHS standard amino coupling method.
- a series of concentration gradients of human OX40-His protein (sinobiological # 10481-H08H) diluted in the same buffer were then loaded into each cycle at a flow rate of 30 ⁇ L/min.
- the chip was regenerated using regeneration reagent provided in the kit.
- the antigen-antibody binding kinetics was traced for 3 minutes, and the dissociation kinetics was traced for 10 minutes.
- the resulting data were analyzed by using BIAevaluation software (GE) with 1:1 (Langmuir) binding model.
- the ka (kon), kd (koff) and KD values of the chimeric antibodies determined by this method are shown in the table below.
- the well-plate was coated with the OX40 ligand (Acrobiosystem, OXL-H52Q8), blocked, added the gradient-diluted antibody to be tested (the antibody was diluted in a solution comprising human Bio-OX40-FC (Acrobiosystem, OX40-H5255, labeled with biotin), pre-incubated for 40 minutes, and then added into the plate), incubated for 40 minute, and washed.
- SA-HRP Jackson Immunoresearch, 016-030-084
- the developing solution and stop solution were added, and the OD value was measured. The results are shown in the table below.
- the well-plate was coated with anti-CD3 antibody (Chempartner, A05-001), placed at 4° C. overnight and washed for 3 times with PBS; Jurkat-NF-Kb luc-hOX40 cells (ATCC, TIB-152, a stable cell line constructed by Shanghai ChemPartner) and Raji cells (ATCC, CCL-86) were harvested. The two kinds of cells were re-suspended and mixed. 50 ⁇ l/well of the diluted antibody to be tested and 50 ⁇ l/well of the mixed two kinds of cells were added to the plate, and the plate was incubated at 37° C. in 5% CO 2 incubator for 5 hours.
- One-Glo TM luciferase reagent (Promega, Cat# E6120) was added to each well, and incubated at room temperature for more than 3 minutes. The luminescent signal was measured on the instrument, RLU reading was recorded. The results are shown in Table 12. The results show that both 2G3 and 4B5 can effectively activate the reporter gene.
- CD4+ memory T cells were isolated and added together with the antibody to be tested to a 96-well plate coated with anti-CD3 antibody (Chempartner, A05-001), co-incubated at 37° C. for 72 hours, the supernatant was collected to detect IFN- ⁇ .
- the results are shown in FIG. 2 and Table 13. The results show that GPX4, 4B5 and 2G3 can significantly enhance the release of IFN- ⁇ , and 2G3 can achieve the maximum stimulating effect at lOng/mL.
- B-hTNFRSF4 (OX40) humanized mice (B-hTNFRSF4 (OX40) humanized mice, from Biocytogen Jiangsu Gene Biotechnology Co., Ltd.), female, 17 to 20 g, 6 to 7 week old.
- the MC38 tumor cells 7 at logarithmic growth phase were collected (purchased from Nanjing Yinhe Biomedicine Co., Ltd.), the cell concentration was adjusted to 5 ⁇ 10 6 /mL with PBS buffer, and 0.1 mL of cell suspension was inoculated to the flanks of OX40 mice. The mice were monitored after inoculation for the growth of tumors. On day 7 after inoculation, the average tumor volume in the flank of tumor-bearing mice reached 102.5 mm 3 . Mice were divided into groups according to the tumor size, administrated and monitored. The grouping information is shown in Table 14.
- the OX40 humanized antibody was tested for its inhibitory effect on the growth of MC38 colon cancer cell xenograft in mice.
- tumor was measured twice a week using a caliper.
- Tumor growth xenograft TGI (%) [1 ⁇ T/C] ⁇ 100.
- the weight of all tumor-bearing mice was measured twice a week.
- the average tumor volume of IgG1 control group reached 1732.593 mm 3 ; and the average tumor volume of the test compound 2G3 low-dose administration group (0.3 mg/kg), medium-dose administration group (2G3, lmg/kg) and high-dose administration group (2G, 3 mg/kg) reached 930.37 mm 3 , 303.49 mm 3 and 155.79 mm 3 , respectively.
- the medium and high-dose group significantly inhibited the tumor growth, when compared with the control group (**P ⁇ 0.01), and a preliminary dose-dependent relationship was observed, with the tumor growth inhibition rate of up to 49%, 88% and 97.0%, respectively.
- the average tumor volume in the 3 mg/kg GPX4 group was 362.47 mm 3 , which was significantly different from that of control group, and 3 mg/kg GPX4 group also showed significant tumor growth inhibition (*P ⁇ 0.05), with the tumor growth inhibition rate of up to 84%.
- mice were euthanized, and the subcutaneous xenograft mass was removed from the tumor-bearing mice and weighed.
- the average weight of tumor mass in the control group was 1.568 g; as for the test compound 2G3 in the low-dose group (0.3 mg/kg), medium-dose group (lmg/kg) and high-dose group (3 mg/kg), the average tumor weight reached 0.926 g, 0.251 g and 0.181 g, respectively; the medium and high-dose group significantly inhibited the tumor growth, when compared with the control group (**P ⁇ 0.01).
- the average tumor weight was 0.372 g, which was significantly different from that of the control group, and GPX4 (3 mg/kg) administration group also showed a significant inhibitory effect on the growth of MC38 tumor cells (**P ⁇ 0.01).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811128669.3 | 2018-09-26 | ||
CN201811128669 | 2018-09-26 | ||
CN201811417666 | 2018-11-26 | ||
CN201811417666.1 | 2018-11-26 | ||
PCT/CN2019/107787 WO2020063660A1 (zh) | 2018-09-26 | 2019-09-25 | 抗ox40抗体、其抗原结合片段及其医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210355229A1 true US20210355229A1 (en) | 2021-11-18 |
Family
ID=69952440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/278,259 Pending US20210355229A1 (en) | 2018-09-26 | 2019-09-25 | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210355229A1 (pt) |
EP (1) | EP3858857A1 (pt) |
JP (1) | JP2022502417A (pt) |
KR (1) | KR20210069058A (pt) |
CN (1) | CN112513088B (pt) |
AU (1) | AU2019347934A1 (pt) |
BR (1) | BR112021005169A2 (pt) |
CA (1) | CA3113541A1 (pt) |
MX (1) | MX2021003168A (pt) |
TW (1) | TW202035455A (pt) |
WO (1) | WO2020063660A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114106173A (zh) * | 2020-08-26 | 2022-03-01 | 上海泰槿生物技术有限公司 | 抗ox40抗体、其药物组合物及应用 |
CN114106174A (zh) * | 2020-08-27 | 2022-03-01 | 苏州景涞医疗科技有限公司 | 低毒性抗ox40抗体、其药物组合物及应用 |
CN114515335A (zh) * | 2020-11-19 | 2022-05-20 | 百奥泰生物制药股份有限公司 | 抗ox40抗体在治疗肿瘤或癌症中的应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CN101668776A (zh) * | 2007-02-27 | 2010-03-10 | 健泰科生物技术公司 | 拮抗剂ox40抗体及其在炎性和自身免疫疾病的治疗中的用途 |
CN103221427B (zh) * | 2010-08-23 | 2016-08-24 | 德克萨斯州立大学董事会 | 抗ox40抗体和使用其的方法 |
EA036047B1 (ru) * | 2011-07-11 | 2020-09-18 | Икнос Сайенсиз Са | Антитела, которые связываются с ox40, и их применение |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
MA39355B2 (fr) * | 2014-03-31 | 2021-04-30 | Genentech Inc | Anticorps anti-ox40 et procédés d'utilisation correspondants |
LT3126394T (lt) | 2014-03-31 | 2020-01-27 | F. Hoffmann-La Roche Ag | Antikūnai prieš ox40 ir jų naudojimo būdai |
EP3292152A1 (en) * | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
PE20180926A1 (es) * | 2015-05-29 | 2018-06-08 | Bristol Myers Squibb Co | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos |
AU2016364891A1 (en) | 2015-12-03 | 2018-06-07 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
US10442866B1 (en) | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
-
2019
- 2019-09-25 EP EP19867097.8A patent/EP3858857A1/en not_active Withdrawn
- 2019-09-25 BR BR112021005169-4A patent/BR112021005169A2/pt not_active Application Discontinuation
- 2019-09-25 WO PCT/CN2019/107787 patent/WO2020063660A1/zh active Application Filing
- 2019-09-25 MX MX2021003168A patent/MX2021003168A/es unknown
- 2019-09-25 CN CN201980050221.0A patent/CN112513088B/zh active Active
- 2019-09-25 AU AU2019347934A patent/AU2019347934A1/en not_active Abandoned
- 2019-09-25 US US17/278,259 patent/US20210355229A1/en active Pending
- 2019-09-25 JP JP2021517014A patent/JP2022502417A/ja active Pending
- 2019-09-25 KR KR1020217011102A patent/KR20210069058A/ko unknown
- 2019-09-25 TW TW108134634A patent/TW202035455A/zh unknown
- 2019-09-25 CA CA3113541A patent/CA3113541A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2019347934A1 (en) | 2021-04-08 |
CN112513088B (zh) | 2023-05-16 |
WO2020063660A1 (zh) | 2020-04-02 |
CN112513088A (zh) | 2021-03-16 |
BR112021005169A2 (pt) | 2021-06-15 |
KR20210069058A (ko) | 2021-06-10 |
EP3858857A1 (en) | 2021-08-04 |
CA3113541A1 (en) | 2020-04-02 |
TW202035455A (zh) | 2020-10-01 |
MX2021003168A (es) | 2021-05-14 |
JP2022502417A (ja) | 2022-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11981733B2 (en) | LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof | |
US11365255B2 (en) | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
EP3712170A1 (en) | Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof | |
JP2021513331A (ja) | 抗b7−h4抗体、その抗原結合断片及びその医薬用途 | |
EP3741777A1 (en) | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
EP3632932A1 (en) | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof | |
EP3744734A1 (en) | Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof | |
US20210355229A1 (en) | An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use | |
CN110790839A (zh) | 抗pd-1抗体、其抗原结合片段及医药用途 | |
TW201916890A (zh) | 抗pd-1抗體和抗lag-3抗體聯合在製備治療腫瘤的藥物中的用途 | |
WO2021190582A1 (zh) | 一种抗ox40抗体药物组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: JIANGSU HENGRUI MEDICINE CO., LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIAO, CHENG;XU, ZUPENG;JIANG, JIAHUA;AND OTHERS;REEL/FRAME:055681/0062 Effective date: 20210317 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |